GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ustekinumab   Click here for help

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
Approved drug Immunopharmacology Ligand
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
ustekinumab-auub; ABP 654Wezlana; WezenlaAmgenApproved (2023 FDA, 2024 EMA)As per reference agent; Interchangeable with reference agent
ustekinumab-aekn; AVT04Selarsdi; UzpruvoAlvotech/Teva Pharmaceuticals/STADA ArzneimittelApproved (2024 FDA & EMA)As per reference agent
ustekinumab-ttwe; SB17Pyzchiva; Epyztek; EksunbiSandoz/Samsung BioepisApproved (2024 FDA, EMA and S Korea MFDS)As per reference agent; Interchangeable with reference agent*
ustekinumab; CT-P43SteQeymaCelltrionApproved (2024 EMA)As per reference agent
ustekinumab-aauz; FYB202Otulfi; Fymskina Fresenius Kabi/Formycon Approved (2024 EMA & FDA)As per reference agent; available as subcutaneous and intravenous formulations
ustekinumab-srlf; DMB-3115Imuldosa/AbsimkyAccord BioPharma/Intas PharmaceuticalsApproved (2024 EMA & FDA)As per reference agent
ustekinumab-kfce; Bmab1200Yesintek Biocon BiologicsApproved (2024 FDA, 2025 EMA)As per reference agent
ustekinumab-hmny; BAT2206StarjemzaBio-Thera Solutions/Hikma PharmaceuticalsApproved (2025 FDA)As per reference agent

*After expiry of the period of exclusivity for the first interchangeable biosimilar product.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
 An anti-IL-12B therapy approved to treat psoriasis.
Psoriatic arthritis Disease Ontology: DOID:9008
 An anti-IL-12B therapy approved to treat PsA.
Ulcerative colitis Disease Ontology: DOID:8577
OMIM: 266600
Orphanet: ORPHA771
 FDA approved for the treatment of moderate-severe UC in October 2019. Results from Phase 3 clinical trial NCT02407236 showed that ustekinumab was more effective than placebo as measured by induction and maintainance of clinical remission. 2